NCT02908906View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

413

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

November 17, 2023

Study Completion Date

December 31, 2026

Conditions

Neoplasms

Interventions

DRUG

JNJ-63723283

JNJ-63723283 will be administered by IV infusion or SC injection or infusion.

Trial Locations (20)

Unknown

St Louis

Pittsburgh

Chisinau

Bialystok

Warsaw

Moscow

Pyatigorsk

Saint Petersburg

Badalona

Barcelona

Madrid

Málaga

Pamplona

Seville

Valencia

Gothenburg

Glasgow

London

Manchester

Newcastle upon Tyne

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02908906 - A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers | Biotech Hunter | Biotech Hunter